Satsuma Pharmaceuticals, Inc.
CIK 0001692830
Revenue (TTM)
—
Q1 May 2023
Net Income (TTM)
−$57.22M
−36.9% YoY
Q1 May 2023
EPS Diluted (TTM)
−$1.80
−25.1% YoY
Q1 May 2023
Gross Margin
—
Q1 May 2023
Operating Margin
—
Q1 May 2023
Net Margin
—
Q1 May 2023
Free Cash Flow (TTM)
−$48.81M
Q1 May 2023
Cash
$19.53M
Q1 May 2023
Total Debt
$1.42M
Q1 May 2023
Shares Outstanding
33.15M sh
Q1 May 2023
Revenue & Net Income
EPS (Diluted)
Cash Flow
Revenue Growth (YoY)
No data available for this metric.